Agency Faces Uncertainty Amid Staffing Upheaval And Policy Shifts
The FDA faced a tumultuous 2025, marked by significant leadership changes, a massive workforce reduction, and reversals of guidance that led to surprise rejections. Despite these challenges, the agency approved 56 novel therapies last year. As 2026 gets underway, biopharma companies are responding to sweeping vaccine changes while concerns surface about the politicization of the agency, according to BioSpace.
Agency Faces Uncertainty Amid Staffing Upheaval And Policy Shifts
The FDA faced a tumultuous 2025, marked by significant leadership changes, a massive workforce reduction, and reversals of guidance that led to surprise rejections. Despite these challenges, the agency approved 56 novel therapies last year. As 2026 gets underway, biopharma companies are responding to sweeping vaccine changes while concerns surface about the politicization of the agency, according to BioSpace.